Lytix Biopharma is advancing innovative cancer therapies through its proprietary technology platform, primarily centered around its lead candidate, LTX-315. This first-in-class oncolytic peptide is designed to selectively target and disrupt cancer cell membranes, leading to necrotic cell death and the release of tumor antigens. This process not only stimulates a robust immune response but also enhances the infiltration of T cells into the tumor microenvironment, effectively converting "cold" tumors into "hot" tumors. LTX-315 has shown promising results in various Phase I/II clinical studies, particularly in skin cancers such as melanoma and basal cell carcinoma, where it is being evaluated both as a monotherapy and in combination with immune checkpoint inhibitors like pembrolizumab.

In addition to LTX-315, Lytix Biopharma is also developing LTX-401, a small molecule aimed at treating deep-seated tumors. Similar to LTX-315, LTX-401 has demonstrated strong anticancer effects and the ability to stimulate T-cell infiltration in preclinical models. Both compounds leverage the principles of immuno-oncology, aiming to enhance the efficacy of existing cancer therapies by reprogramming the tumor microenvironment and overcoming resistance mechanisms. The ongoing clinical trials and research underscore Lytix Biopharma's commitment to addressing the challenges of cancer treatment through innovative immunotherapeutic strategies.

Norway

Lytix Biopharma is a  clinical-stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. 

Lead compound LTX-315 provides access to antigens by using the patient’s own tumor as source of antigens and turns cold tumors hot. 

Local treatment with LTX-315 targets the first step in the cancer immunity cycle with a potential cornerstone position in immunotherapy.

Lytix Biopharma

Company Details